Table of Content
1 INTRODUCTION (Page No. - 21)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 STUDY SCOPE
1.3.1 HEMOSTATS MARKET
1.3.2 GEOGRAPHIC SCOPE
1.3.3 YEARS CONSIDERED
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 26)
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
FIGURE 1 HEMOSTATS MARKET: RESEARCH DESIGN METHODOLOGY
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Primary sources
2.2.2.2 Key data from primary sources
2.2.2.3 Key industry insights
2.2.2.4 Breakdown of primary interviews
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Approach 1: Company revenue estimation approach
FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
2.3.1.2 Approach 2: Presentations of companies and primary interviews
2.3.1.3 Growth forecast
2.3.1.4 CAGR projections
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3.2 TOP-DOWN APPROACH
FIGURE 6 HEMOSTATS INDUSTRY: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.5 MARKET SHARE ANALYSIS
2.6 STUDY ASSUMPTIONS
2.7 GROWTH RATE ASSUMPTIONS
2.8 RISK ASSESSMENT
2.8.1 RISK ASSESSMENT: HEMOSTATS MARKET
2.9 RECESSION IMPACT
3 EXECUTIVE SUMMARY (Page No. - 39)
FIGURE 8 HEMOSTATS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 9 HEMOSTATS INDUSTRY, BY FORMULATION, 2023 VS. 2028 (USD MILLION)
FIGURE 10 MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
FIGURE 11 MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)
4 PREMIUM INSIGHTS (Page No. - 42)
4.1 HEMOSTATS MARKET OVERVIEW
FIGURE 12 GROWING NEED TO MANAGE BLOOD LOSS IN PATIENTS DURING SURGICAL PROCEDURES TO DRIVE MARKET GROWTH
4.2 HEMOSTATS INDUSTRY SHARE, BY TYPE, 2023 VS. 2028
FIGURE 13 OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATS TO CONTINUE TO DOMINATE MARKET IN 2028
4.3 MARKET SHARE, BY FORMULATION, 2023 VS. 2028
FIGURE 14 MATRIX & GEL HEMOSTATS SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD
4.4 MARKET SHARE, BY APPLICATION, 2023 VS. 2028
FIGURE 15 ORTHOPEDIC SURGERY SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
4.5 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 16 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN MARKET DURING FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 45)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 17 HEMOSTATS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Growing volume of surgical procedures performed
TABLE 1 TOTAL NUMBER OF KNEE REPLACEMENTS, 2021
TABLE 2 TOTAL NUMBER OF CORONARY ARTERY BYPASS GRAFT PROCEDURES, 2021
5.2.1.2 Rising focus on R&D
5.2.1.3 Rising focus on effective blood loss management in patients during surgeries
5.2.2 RESTRAINTS
5.2.2.1 Side effects and allergic reactions associated with hemostats
5.2.3 OPPORTUNITIES
5.2.3.1 Growth opportunities in emerging economies
TABLE 3 COST OF SURGICAL PROCEDURES: US VS. INDIA (USD)
5.2.3.2 Growing number of hospitals
5.2.4 CHALLENGES
5.2.4.1 Stringent regulatory framework
5.2.4.2 Dearth of skilled personnel for effective use of hemostats
5.2.4.3 High cost of hemostats
5.3 PRICING ANALYSIS
5.3.1 INDICATIVE PRICING MODEL ANALYSIS OF MARKET PLAYERS
TABLE 4 INDICATIVE PRICING FOR HEMOSTATS
5.3.2 AVERAGE SELLING PRICE OF HEMOSTATS, BY REGION
TABLE 5 AVERAGE SELLING PRICE OF HEMOSTATS
5.4 VALUE CHAIN ANALYSIS
FIGURE 18 VALUE CHAIN ANALYSIS OF HEMOSTATS INDUSTRY: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
5.5 SUPPLY CHAIN ANALYSIS
FIGURE 19 MARKET: SUPPLY CHAIN ANALYSIS
5.6 PATENT ANALYSIS
FIGURE 20 PATENT ANALYSIS FOR HEMOSTATS (JANUARY 2013–DECEMBER 2022)
5.6.1 LIST OF MAJOR PATENTS
5.7 TRADE ANALYSIS
5.7.1 TRADE ANALYSIS FOR HEMOSTATS
TABLE 6 IMPORT DATA FOR HEMOSTATS, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 7 EXPORT DATA FOR HEMOSTATS, BY COUNTRY, 2018–2022 (USD MILLION)
5.8 ECOSYSTEM ANALYSIS
FIGURE 21 MARKET: ECOSYSTEM ANALYSIS
5.8.1 MARKET: ROLE IN ECOSYSTEM
5.9 PORTER’S FIVE FORCES ANALYSIS
TABLE 8 MARKET: PORTER’S FIVE FORCES ANALYSIS
5.9.1 THREAT OF NEW ENTRANTS
5.9.2 THREAT OF SUBSTITUTES
5.9.3 BARGAINING POWER OF SUPPLIERS
5.9.4 BARGAINING POWER OF BUYERS
5.9.5 INTENSITY OF COMPETITIVE RIVALRY
5.10 REGULATORY LANDSCAPE
TABLE 9 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 11 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 12 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.10.1 NORTH AMERICA
5.10.1.1 US
TABLE 13 CLASSIFICATION OF MEDICAL DEVICES BY US FDA
FIGURE 22 PREMARKET NOTIFICATION: 510(K) APPROVAL FOR MEDICAL DEVICES
5.10.1.2 Canada
FIGURE 23 APPROVAL PROCESS FOR CLASS III MEDICAL DEVICES IN CANADA
5.10.2 EUROPE
FIGURE 24 CE APPROVAL PROCESS IN EUROPE FOR HEMOSTATS
5.10.3 ASIA PACIFIC
5.10.3.1 Japan
TABLE 14 CLASSIFICATION OF MEDICAL DEVICES AND REVIEWING BODY IN JAPAN
5.10.3.2 China
TABLE 15 NMPA MEDICAL DEVICES CLASSIFICATION
5.10.3.3 India
5.11 TECHNOLOGY ANALYSIS
5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 25 REVENUE SHIFT IN MARKET
6 HEMOSTATS MARKET, BY TYPE (Page No. - 69)
6.1 INTRODUCTION
TABLE 16 HEMOSTATS INDUSTRY, BY TYPE, 2018–2021 (USD MILLION)
TABLE 17 MARKET, BY TYPE, 2022–2028 (USD MILLION)
6.2 PRIMARY NOTES
6.2.1 KEY PRIMARY INSIGHTS
6.3 OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATS
6.3.1 GROWING AVAILABILITY OF ORC-BASED HEMOSTATIC AGENTS ACROSS UNTAPPED MARKETS TO DRIVE GROWTH
TABLE 18 MAJOR PRODUCTS IN OXIDIZED REGENERATED CELLULOSE-BASED MARKET
TABLE 19 OXIDIZED REGENERATED CELLULOSE-BASED MARKET, BY REGION, 2018–2021 (USD MILLION)
TABLE 20 OXIDIZED REGENERATED CELLULOSE-BASED MARKET, BY REGION, 2022–2028 (USD MILLION)
6.4 THROMBIN-BASED HEMOSTATS
6.4.1 DEVELOPMENTS IN RECOMBINANT THROMBIN PRODUCTS TO SUPPORT GROWTH
TABLE 21 MAJOR PRODUCTS IN THROMBIN-BASED MARKET
TABLE 22 THROMBIN-BASED MARKET, BY REGION, 2018–2021 (USD MILLION)
TABLE 23 THROMBIN-BASED MARKET, BY REGION, 2022–2028 (USD MILLION)
6.5 COMBINATION HEMOSTATS
6.5.1 ADVANCEMENTS IN COMBINATION MATERIALS TO PROPEL MARKET GROWTH
TABLE 24 MAJOR PRODUCTS IN COMBINATION MARKET
TABLE 25 COMBINATION MARKET, BY REGION, 2018–2021 (USD MILLION)
TABLE 26 COMBINATION MARKET, BY REGION, 2022–2028 (USD MILLION)
6.6 GELATIN-BASED HEMOSTATS
6.6.1 HIGH ELASTICITY OFFERED BY GELATIN-BASED HEMOSTATS TO BOOST DEMAND
TABLE 27 MAJOR PRODUCTS IN GELATIN-BASED MARKET
TABLE 28 GELATIN-BASED MARKET, BY REGION, 2018–2021 (USD MILLION)
TABLE 29 GELATIN-BASED MARKET, BY REGION, 2022–2028 (USD MILLION)
6.7 COLLAGEN-BASED HEMOSTATS
6.7.1 LOW COST AND REDUCED RISK OF DISEASE TRANSMISSION TO PROMOTE ADOPTION OF COLLAGEN-BASED HEMOSTATS
TABLE 30 MAJOR PRODUCTS IN COLLAGEN-BASED MARKET
TABLE 31 COLLAGEN-BASED MARKET, BY REGION, 2018–2021 (USD MILLION)
TABLE 32 COLLAGEN-BASED MARKET, BY REGION, 2022–2028 (USD MILLION)
6.8 OTHER HEMOSTATS
TABLE 33 OTHER MARKET, BY REGION, 2018–2021 (USD MILLION)
TABLE 34 OTHER MARKET, BY REGION, 2022–2028 (USD MILLION)
7 HEMOSTATS MARKET, BY FORMULATION (Page No. - 81)
7.1 INTRODUCTION
TABLE 35 HEMOSTATS INDUSTRY, BY FORMULATION, 2018–2021 (USD MILLION)
TABLE 36 MARKET, BY FORMULATION, 2022–2028 (USD MILLION)
7.2 MATRIX & GEL HEMOSTATS
7.2.1 ABILITY OF MATRIX & GEL HEMOSTATS TO ENHANCE PLATELET AGGREGATION TO BOOST MARKET
TABLE 37 MATRIX & GEL MARKET, BY REGION, 2018–2021 (USD MILLION)
TABLE 38 MATRIX & GEL MARKET, BY REGION, 2022–2028 (USD MILLION)
7.3 SHEET & PAD HEMOSTATS
7.3.1 ABILITY TO CUT SHEET & PAD HEMOSTATS INTO ANY SHAPE OR SIZE TO FUEL ADOPTION
TABLE 39 SHEET & PAD MARKET, BY REGION, 2018–2021 (USD MILLION)
TABLE 40 SHEET & PAD MARKET, BY REGION, 2022–2028 (USD MILLION)
7.4 SPONGE HEMOSTATS
7.4.1 GROWING ACCEPTANCE OF SPONGE HEMOSTATS TO FUEL UPTAKE
TABLE 41 SPONGE MARKET, BY REGION, 2018–2021 (USD MILLION)
TABLE 42 SPONGE MARKET, BY REGION, 2022–2028 (USD MILLION)
7.5 POWDER HEMOSTATS
7.5.1 ABILITY TO SPRAY POWDER FORMULATIONS DIRECTLY ON WOUNDS TO FUEL DEMAND
TABLE 43 POWDER MARKET, BY REGION, 2018–2021 (USD MILLION)
TABLE 44 POWDER MARKET, BY REGION, 2022–2028 (USD MILLION)
8 HEMOSTATS MARKET, BY APPLICATION (Page No. - 88)
8.1 INTRODUCTION
TABLE 45 HEMOSTATS INDUSTRY, BY APPLICATION, 2018–2021 (USD MILLION)
TABLE 46 MARKET, BY APPLICATION, 2022–2028 (USD MILLION)
8.2 PRIMARY NOTES
8.2.1 KEY PRIMARY INSIGHTS
8.3 ORTHOPEDIC SURGERY
8.3.1 INCREASING INCIDENCE OF SPORTS INJURIES TO SUPPORT MARKET GROWTH
TABLE 47 NUMBER OF KNEE & HIP REPLACEMENTS, 2021
TABLE 48 MARKET FOR ORTHOPEDIC SURGERY, BY REGION, 2018–2021 (USD MILLION)
TABLE 49 MARKET FOR ORTHOPEDIC SURGERY, BY REGION, 2022–2028 (USD MILLION)
8.4 GENERAL SURGERY
8.4.1 INCREASING NUMBER OF HERNIA REPAIR PROCEDURES TO DRIVE GROWTH
TABLE 50 TOTAL NUMBER OF INGUINAL HERNIA REPAIR PROCEDURES, 2021
TABLE 51 MARKET FOR GENERAL SURGERY, BY REGION, 2018–2021 (USD MILLION)
TABLE 52 MARKET FOR GENERAL SURGERY, BY REGION, 2022–2028 (USD MILLION)
8.5 NEUROLOGICAL SURGERY
8.5.1 GROWING PREVALENCE OF NEUROLOGICAL DISORDERS TO DRIVE MARKET GROWTH
TABLE 53 MARKET FOR NEUROLOGICAL SURGERY, BY REGION, 2018–2021 (USD MILLION)
TABLE 54 MARKET FOR NEUROLOGICAL SURGERY, BY REGION, 2022–2028 (USD MILLION)
8.6 CARDIOVASCULAR SURGERY
8.6.1 RISING PREVALENCE OF CVD TO DRIVE ADOPTION OF HEMOSTATS
TABLE 55 MARKET FOR CARDIOVASCULAR SURGERY, BY REGION, 2018–2021 (USD MILLION)
TABLE 56 MARKET FOR CARDIOVASCULAR SURGERY, BY REGION, 2022–2028 (USD MILLION)
8.7 RECONSTRUCTIVE SURGERY
8.7.1 GROWING NUMBER OF COSMETIC SURGERIES TO SUPPORT MARKET GROWTH
TABLE 57 MARKET FOR RECONSTRUCTIVE SURGERY, BY REGION, 2018–2021 (USD MILLION)
TABLE 58 MARKET FOR RECONSTRUCTIVE SURGERY, BY REGION, 2022–2028 (USD MILLION)
8.8 GYNECOLOGICAL SURGERY
8.8.1 GROWING USE OF HEMOSTATS IN C-SECTION PROCEDURES TO CONTROL SURGICAL BLEEDING TO SUPPORT GROWTH
TABLE 59 MARKET FOR GYNECOLOGICAL SURGERY, BY REGION, 2018–2021 (USD MILLION)
TABLE 60 MARKET FOR GYNECOLOGICAL SURGERY, BY REGION, 2022–2028 (USD MILLION)
8.9 OTHER SURGICAL APPLICATIONS
TABLE 61 MARKET FOR OTHER SURGICAL APPLICATIONS, BY REGION, 2018–2021 (USD MILLION)
TABLE 62 MARKET FOR OTHER SURGICAL APPLICATIONS, BY REGION, 2022–2028 (USD MILLION)
9 HEMOSTATS MARKET, BY REGION (Page No. - 101)
9.1 INTRODUCTION
TABLE 63 HEMOSTATS INDUSTRY, BY REGION, 2018–2021 (USD MILLION)
TABLE 64 MARKET, BY REGION, 2022–2028 (USD MILLION)
9.2 NORTH AMERICA
FIGURE 26 NORTH AMERICA: HEMOSTATS MARKET SNAPSHOT
TABLE 65 NORTH AMERICA: MARKET, BY COUNTRY, 2018–2021 (USD MILLION)
TABLE 66 NORTH AMERICA: MARKET, BY COUNTRY, 2022–2028 (USD MILLION)
TABLE 67 NORTH AMERICA: MARKET, BY TYPE, 2018–2021 (USD MILLION)
TABLE 68 NORTH AMERICA: MARKET, BY TYPE, 2022–2028 (USD MILLION)
TABLE 69 NORTH AMERICA: MARKET, BY FORMULATION, 2018–2021 (USD MILLION)
TABLE 70 NORTH AMERICA: MARKET, BY FORMULATION, 2022–2028 (USD MILLION)
TABLE 71 NORTH AMERICA: MARKET, BY APPLICATION, 2018–2021 (USD MILLION)
TABLE 72 NORTH AMERICA: MARKET, BY APPLICATION, 2022–2028 (USD MILLION)
9.2.1 NORTH AMERICA: RECESSION IMPACT
9.2.2 US
9.2.2.1 Strong healthcare infrastructure to support uptake of hemostats
TABLE 73 US: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)
TABLE 74 US: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)
9.2.3 CANADA
9.2.3.1 Growing geriatric population and increasing volume of surgeries to drive demand for hemostats
TABLE 75 SURGICAL PROCEDURES PERFORMED IN CANADA, 2021
TABLE 76 CANADA: KEY MACROINDICATORS
TABLE 77 CANADA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)
TABLE 78 CANADA: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)
9.3 EUROPE
TABLE 79 EUROPE: HEMOSTATS MARKET, BY COUNTRY, 2018–2021 (USD MILLION)
TABLE 80 EUROPE: MARKET, BY COUNTRY, 2022–2028 (USD MILLION)
TABLE 81 EUROPE: MARKET, BY TYPE, 2018–2021 (USD MILLION)
TABLE 82 EUROPE: MARKET, BY TYPE, 2022–2028 (USD MILLION)
TABLE 83 EUROPE: MARKET, BY FORMULATION, 2018–2021 (USD MILLION)
TABLE 84 EUROPE: MARKET, BY FORMULATION, 2022–2028 (USD MILLION)
TABLE 85 EUROPE: MARKET, BY APPLICATION, 2018–2021 (USD MILLION)
TABLE 86 EUROPE: MARKET, BY APPLICATION, 2022–2028 (USD MILLION)
9.3.1 EUROPE: RECESSION IMPACT
9.3.2 GERMANY
9.3.2.1 High healthcare expenditure in Germany to favor market growth
TABLE 87 SURGICAL PROCEDURES PERFORMED IN GERMANY, 2021
TABLE 88 GERMANY: KEY MACROINDICATORS
TABLE 89 GERMANY: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)
TABLE 90 GERMANY: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)
9.3.3 UK
9.3.3.1 Growing volume of hernia repair and cardiovascular surgeries to drive market growth
TABLE 91 SURGICAL PROCEDURES PERFORMED IN UK, 2021
TABLE 92 UK: KEY MACROINDICATORS
TABLE 93 UK: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)
TABLE 94 UK: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)
9.3.4 FRANCE
9.3.4.1 Presence of well-established healthcare system to propel market growth
TABLE 95 SURGICAL PROCEDURES PERFORMED IN FRANCE, 2021
TABLE 96 FRANCE: KEY MACROINDICATORS
TABLE 97 FRANCE: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)
TABLE 98 FRANCE: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)
9.3.5 ITALY
9.3.5.1 Increasing volume of surgeries to drive demand for hemostats
TABLE 99 SURGICAL PROCEDURES PERFORMED IN ITALY, 2021
TABLE 100 ITALY: KEY MACROINDICATORS
TABLE 101 ITALY: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)
TABLE 102 ITALY: MARKET, BY TYPE, 2022–2028 (USD MILLION)
9.3.6 SPAIN
9.3.6.1 Growing healthcare budget and rising efforts to boost local manufacturing of medical products to drive market growth
TABLE 103 SURGICAL PROCEDURES PERFORMED IN SPAIN, 2021
TABLE 104 SPAIN: KEY MACROINDICATORS
TABLE 105 SPAIN: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)
TABLE 106 SPAIN: MARKET, BY TYPE, 2022–2028 (USD MILLION)
9.3.7 RUSSIA
9.3.7.1 Long-term healthcare investment initiatives by government to support market growth
TABLE 107 RUSSIA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)
TABLE 108 RUSSIA: MARKET, BY TYPE, 2022–2028 (USD MILLION)
9.3.8 SWITZERLAND
9.3.8.1 Increasing public health insurance coverage to drive number of surgical procedures
TABLE 109 SURGICAL PROCEDURES PERFORMED IN SWITZERLAND, 2021
TABLE 110 SWITZERLAND: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)
TABLE 111 SWITZERLAND: MARKET, BY TYPE, 2022–2028 (USD MILLION)
9.3.9 BELGIUM
9.3.9.1 Increasing demand for value-based healthcare services to drive market growth
TABLE 112 SURGICAL PROCEDURES PERFORMED IN BELGIUM, 2021
TABLE 113 BELGIUM: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)
TABLE 114 BELGIUM: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)
9.3.10 REST OF EUROPE
TABLE 115 REST OF EUROPE: PERCENTAGE OF GDP ON HEALTHCARE EXPENDITURE, BY COUNTRY
TABLE 116 REST OF EUROPE: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)
TABLE 117 REST OF EUROPE: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)
9.4 ASIA PACIFIC
FIGURE 27 ASIA PACIFIC: HEMOSTATS MARKET SNAPSHOT
TABLE 118 ASIA PACIFIC: MARKET, BY COUNTRY, 2018–2021 (USD MILLION)
TABLE 119 ASIA PACIFIC: MARKET, BY COUNTRY, 2022–2028 (USD MILLION)
TABLE 120 ASIA PACIFIC: MARKET, BY TYPE, 2018–2021 (USD MILLION)
TABLE 121 ASIA PACIFIC: MARKET, BY TYPE, 2022–2028 (USD MILLION)
TABLE 122 ASIA PACIFIC: MARKET, BY FORMULATION, 2018–2021 (USD MILLION)
TABLE 123 ASIA PACIFIC: MARKET, BY FORMULATION, 2022–2028 (USD MILLION)
TABLE 124 ASIA PACIFIC: MARKET, BY APPLICATION, 2018–2021 (USD MILLION)
TABLE 125 ASIA PACIFIC: MARKET, BY APPLICATION, 2022–2028 (USD MILLION)
9.4.1 ASIA PACIFIC: RECESSION IMPACT
9.4.2 CHINA
9.4.2.1 Growing number of hospitals and healthcare policy reforms to drive growth
TABLE 126 CHINA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)
TABLE 127 CHINA: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)
9.4.3 JAPAN
9.4.3.1 Strong healthcare system and rising geriatric population to support market growth
TABLE 128 JAPAN: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)
TABLE 129 JAPAN: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)
9.4.4 INDIA
9.4.4.1 Rising healthcare awareness and favorable government support to propel market growth
TABLE 130 INDIA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)
TABLE 131 INDIA: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)
9.4.5 AUSTRALIA
9.4.5.1 Rising prevalence of chronic diseases to drive market growth
TABLE 132 AUSTRALIA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)
TABLE 133 AUSTRALIA: MARKET, BY TYPE, 2022–2028 (USD MILLION)
9.4.6 SOUTH KOREA
9.4.6.1 Growing number of cosmetic surgeries to drive demand for hemostats
TABLE 134 SURGICAL PROCEDURES IN SOUTH KOREA, 2021
TABLE 135 SOUTH KOREA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)
TABLE 136 SOUTH KOREA: MARKET, BY TYPE, 2022–2028 (USD MILLION)
9.4.7 SINGAPORE
9.4.7.1 Government initiatives to promote healthcare services to support market growth
TABLE 137 SINGAPORE: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)
TABLE 138 SINGAPORE: MARKET, BY TYPE, 2022–2028 (USD MILLION)
9.4.8 NEW ZEALAND
9.4.8.1 Increasing number of hip fractures to propel market growth
TABLE 139 NEW ZEALAND: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)
TABLE 140 NEW ZEALAND: MARKET, BY TYPE, 2022–2028 (USD MILLION)
9.4.9 INDONESIA
9.4.9.1 Lucrative growth opportunities for players to boost market
TABLE 141 INDONESIA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)
TABLE 142 INDONESIA: MARKET, BY TYPE, 2022–2028 (USD MILLION)
9.4.10 MALAYSIA
9.4.10.1 Low healthcare costs, modern medical technology, and highly qualified doctors to favor market growth
TABLE 143 MALAYSIA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)
TABLE 144 MALAYSIA: MARKET, BY TYPE, 2022–2028 (USD MILLION)
9.4.11 REST OF ASIA PACIFIC
TABLE 145 REST OF ASIA PACIFIC: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)
TABLE 146 REST OF ASIA PACIFIC: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)
9.5 LATIN AMERICA
TABLE 147 LATIN AMERICA: HEMOSTATS MARKET, BY COUNTRY, 2018–2021 (USD MILLION)
TABLE 148 LATIN AMERICA: MARKET, BY COUNTRY, 2022–2028 (USD MILLION)
TABLE 149 LATIN AMERICA: MARKET, BY TYPE, 2018–2021 (USD MILLION)
TABLE 150 LATIN AMERICA: MARKET, BY TYPE, 2022–2028 (USD MILLION)
TABLE 151 LATIN AMERICA: MARKET, BY FORMULATION, 2018–2021 (USD MILLION)
TABLE 152 LATIN AMERICA: MARKET, BY FORMULATION, 2022–2028 (USD MILLION)
TABLE 153 LATIN AMERICA: MARKET, BY APPLICATION, 2018–2021 (USD MILLION)
TABLE 154 LATIN AMERICA: MARKET, BY APPLICATION, 2022–2028 (USD MILLION)
9.5.1 LATIN AMERICA: RECESSION IMPACT
9.5.2 BRAZIL
9.5.2.1 Brazil to dominate Latin American market for hemostats
TABLE 155 BRAZIL: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)
TABLE 156 BRAZIL: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)
9.5.3 MEXICO
9.5.3.1 Low-cost surgeries to drive medical tourism in Mexico
TABLE 157 MEXICO: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)
TABLE 158 MEXICO: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)
9.5.4 REST OF LATIN AMERICA
TABLE 159 REST OF LATIN AMERICA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)
TABLE 160 REST OF LATIN AMERICA: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)
9.6 MIDDLE EAST & AFRICA
9.6.1 STRENGTHENING OF HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH
TABLE 161 MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)
TABLE 162 MIDDLE EAST & AFRICA: MARKET, BY TYPE, 2022–2028 (USD MILLION)
TABLE 163 MIDDLE EAST & AFRICA: MARKET, BY FORMULATION, 2018–2021 (USD MILLION)
TABLE 164 MIDDLE EAST & AFRICA: MARKET, BY FORMULATION, 2022–2028 (USD MILLION)
TABLE 165 MIDDLE EAST & AFRICA: MARKET, BY APPLICATION, 2018–2021 (USD MILLION)
TABLE 166 MIDDLE EAST & AFRICA: MARKET, BY APPLICATION, 2022–2028 (USD MILLION)
9.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
10 COMPETITIVE LANDSCAPE (Page No. - 161)
10.1 OVERVIEW
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN HEMOSTATS MARKET
TABLE 167 OVERVIEW OF STRATEGIES DEPLOYED BY KEY HEMOSTAT MANUFACTURING COMPANIES
10.3 REVENUE ANALYSIS
FIGURE 28 REVENUE ANALYSIS OF TOP PLAYERS IN HEMOSTATS INDUSTRY (2018–2022)
10.4 MARKET SHARE ANALYSIS
FIGURE 29 MARKET SHARE ANALYSIS OF TOP PLAYERS IN HEMOSTATS INDUSTRY (2022)
TABLE 168 HEMOSTATS INDUSTRY: DEGREE OF COMPETITION
10.5 COMPANY EVALUATION MATRIX
10.5.1 LIST OF EVALUATED VENDORS
10.5.2 STARS
10.5.3 EMERGING LEADERS
10.5.4 PERVASIVE PLAYERS
10.5.5 PARTICIPANTS
FIGURE 30 HEMOSTATS INDUSTRY: COMPANY EVALUATION MATRIX (2022)
10.5.6 COMPANY FOOTPRINT
10.5.6.1 Product & regional footprint analysis
FIGURE 31 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS OF TOP PLAYERS IN HEMOSTATS INDUSTRY
TABLE 169 HEMOSTATS INDUSTRY: COMPETITIVE BENCHMARKING OF KEY PLAYERS
TABLE 170 COMPANY FOOTPRINT, BY TYPE
TABLE 171 COMPANY FOOTPRINT, BY REGION
10.6 START-UP/SME EVALUATION MATRIX
10.6.1 PROGRESSIVE COMPANIES
10.6.2 RESPONSIVE COMPANIES
10.6.3 DYNAMIC COMPANIES
10.6.4 STARTING BLOCKS
FIGURE 32 HEMOSTATS MARKET: START-UP/SME EVALUATION MATRIX (2022)
10.7 COMPETITIVE SCENARIO
10.7.1 PRODUCT LAUNCHES & APPROVALS
TABLE 172 KEY PRODUCT LAUNCHES & APPROVALS (JANUARY 2018–OCTOBER 2023)
10.7.2 DEALS
TABLE 173 KEY DEALS (JANUARY 2018–OCTOBER 2023)
10.7.3 OTHER KEY DEVELOPMENTS
TABLE 174 OTHER KEY DEVELOPMENTS (JANUARY 2018–OCTOBER 2023)
11 COMPANY PROFILES (Page No. - 174)
(Business overview, Products offered, Recent developments & MnM View)*
11.1 KEY PLAYERS
11.1.1 JOHNSON & JOHNSON
TABLE 175 JOHNSON & JOHNSON: BUSINESS OVERVIEW
FIGURE 33 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2022)
11.1.2 BAXTER INTERNATIONAL
TABLE 176 BAXTER INTERNATIONAL: BUSINESS OVERVIEW
FIGURE 34 BAXTER INTERNATIONAL: COMPANY SNAPSHOT (2022)
11.1.3 PFIZER INC.
TABLE 177 PFIZER INC.: BUSINESS OVERVIEW
FIGURE 35 PFIZER INC.: COMPANY SNAPSHOT (2022)
11.1.4 B. BRAUN SE
TABLE 178 B. BRAUN SE: BUSINESS OVERVIEW
FIGURE 36 B. BRAUN SE: COMPANY SNAPSHOT (2022)
11.1.5 BECTON, DICKINSON AND COMPANY
TABLE 179 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
FIGURE 37 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)
11.1.6 TELEFLEX INCORPORATED
TABLE 180 TELEFLEX INCORPORATED: BUSINESS OVERVIEW
FIGURE 38 TELEFLEX INCORPORATED: COMPANY SNAPSHOT (2022)
11.1.7 MEDTRONIC PLC
TABLE 181 MEDTRONIC PLC: BUSINESS OVERVIEW
FIGURE 39 MEDTRONIC PLC: COMPANY SNAPSHOT (2022)
11.1.8 HEMOSTASIS, LLC
TABLE 182 HEMOSTASIS, LLC: BUSINESS OVERVIEW
11.1.9 STRYKER CORPORATION
TABLE 183 STRYKER CORPORATION: BUSINESS OVERVIEW
FIGURE 40 STRYKER CORPORATION: COMPANY SNAPSHOT (2022)
11.1.10 INTEGRA LIFESCIENCES
TABLE 184 INTEGRA LIFESCIENCES: BUSINESS OVERVIEW
FIGURE 41 INTEGRA LIFESCIENCES: COMPANY SNAPSHOT (2022)
11.1.11 ADVANCED MEDICAL SOLUTIONS GROUP PLC
TABLE 185 ADVANCED MEDICAL SOLUTIONS GROUP PLC: BUSINESS OVERVIEW
FIGURE 42 ADVANCED MEDICAL SOLUTIONS GROUP PLC: COMPANY SNAPSHOT (2022)
11.1.12 SAMYANG HOLDINGS CORPORATION
TABLE 186 SAMYANG CORPORATION: BUSINESS OVERVIEW
FIGURE 43 SAMYANG CORPORATION: COMPANY SNAPSHOT (2022)
*Details on Business overview, Products offered, Recent developments & MnM View might not be captured in case of unlisted companies.
11.2 OTHER PLAYERS
11.2.1 MARINE POLYMER TECHNOLOGIES, INC.
11.2.2 GELITA MEDICAL GMBH
11.2.3 DILON TECHNOLOGIES, INC.
11.2.4 BETATECH MEDICAL
11.2.5 MERIL LIFE SCIENCES PVT. LTD.
11.2.6 BIOCER ENTWICKLUNGS-GMBH
11.2.7 UNILENE
11.2.8 KATSAN MEDICAL DEVICES
11.2.9 TRICOL BIOMEDICAL
11.2.10 3-D MATRIX MEDICAL TECHNOLOGY
11.2.11 HEMOSTAT MEDICAL GMBH
11.2.12 MEDTRADE PRODUCTS LIMITED
11.2.13 ALTAYLAR MEDICAL
12 APPENDIX (Page No. - 215)
12.1 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.2 CUSTOMIZATION OPTIONS
12.3 RELATED REPORTS
12.4 AUTHOR DETAILS
US $
Euro €
GBP £
